4D Molecular Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, 4D Molecular Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 4 currently recruiting early-phase tilt top decile by trial count

4D Molecular Therapeutics: 9 sponsored US clinical trials, 4 recruiting.

4D Molecular Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is X-Linked Retinitis Pigmentosa, with 1 trials.

Top-decile sponsor footprint

4D Molecular Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759
RECRUITING Phase 3

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT06864988
RECRUITING Phase 2

4D-710 in Adult Patients With Cystic Fibrosis

NCT05248230
RECRUITING Phase 1

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

NCT05197270
ACTIVE NOT RECRUITING Phase 2

4D-150 in Patients With Diabetic Macular Edema

NCT05930561
ACTIVE NOT RECRUITING Phase 1

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease

NCT04519749
ACTIVE NOT RECRUITING Phase 1

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

NCT04517149
ACTIVE NOT RECRUITING Phase 1

Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

NCT04483440
TERMINATED

"Natural History" Study of Choroideremia

NCT02994368

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2

Therapeutic Areas

X-Linked Retinitis Pigmentosa 1
Macular Neovascularization Secondary to Age-Related Macular Degeneration 1
Cystic Fibrosis Lung 1
Diabetic Macular Edema 1
Fabry Disease 1
Choroideremia 1
Diabetic Retinopathy 1
Neovascular Age-related Macular Degeneration (nAMD) 1
Neovascular (Wet) Age-Related Macular Degeneration 1

What is open in the 4D Molecular Therapeutics pipeline

4 recruiting of 9 indexed (44% open).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: X-Linked Retinitis Pigmentosa (1 trial), 8 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

4D Molecular Therapeutics: open-pipeline peers nationwide

Peers matched on 9 registered trials and 44% open enrollment, not the therapeutic-area sidebar.

4D Molecular Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 51015202530 0%10%20%30%40%50% Total trials Recruiting share 4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyAcacia PharmaAmerican Heart AssociationAscendis Pharma A/SCullinan TherapeuticsMarquette University
4D Molecular Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

4D Molecular Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 44% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this 4D Molecular Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of 4D Molecular Therapeutics or any single study.

  • 4 of 4D Molecular Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • X-Linked Retinitis Pigmentosa is the condition 4D Molecular Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See X-Linked Retinitis Pigmentosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

4D Molecular Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.